Expert Interview
Discussing the data from the 2023 Triple Meeting on Amgen's AMG 193 in solid tumors with MTAP deficiency with the Lead Presenter
Ticker(s): AMGNInstitution: MD Anderson
- Associate Professor in the Department of Investigational Cancer Therapeutics, Associate Medical Director for the Institute for Personalized Cancer Therapy and Clinical Co-Director of the Precision Oncology Decision Support Group at MD Anderson.
- Specializes in early drug development, biomarker discovery, personalized cancer medicine, and neuro-oncology.
- Area of expertise includes First-in-human studies of targeted therapies, rational combinations of novel therapies, biomarker-driven trials and trials in molecularly selected populations.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
